AAOMS Annual Meeting

Conference Coverage

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alerts
FDA Alerts
FDA Approves New Option for Type 2 Diabetes (INVOKAMET XR)
09/21/2016
The FDA has approved INVOKAMET XR for use as a supplement to diet and exercise for improved control of blood glucose levels in adults with type 2 diabetes.
09/21/2016
FDA Alerts
FDA Alerts
FDA Approves New Option for Secondary CV Prevention
09/15/2016
The FDA approved Yosprala to treat patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events.
09/15/2016
FDA Alerts
FDA Alerts
FDA Approves New Option for Secondary CV Prevention
09/15/2016
The FDA approved Yosprala to treat patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events.
09/15/2016
FDA Alerts
FDA Alerts
FDA Approves New Option for Secondary CV Prevention
09/15/2016
The FDA approved Yosprala to treat patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events.
09/15/2016
Medication Prescribing
Medication Prescribing
FDA Issues Strong Warnings Against Combining Opioids and Benzodiazepine
09/01/2016
The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.
09/01/2016
Medication Prescribing
Medication Prescribing
FDA Issues Strong Warnings Against Combining Opioids and Benzodiazepine
09/01/2016
The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.
09/01/2016
Medication Prescribing
Medication Prescribing
FDA Issues Strong Warnings Against Combining Opioids and Benzodiazepine
09/01/2016
The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.
09/01/2016
FDA Alerts
FDA Alerts
FDA Approves Biosimilar for Various Inflammatory Diseases
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016
FDA Alerts
FDA Alerts
FDA Approves Biosimilar for Various Inflammatory Diseases
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016
FDA Alerts
FDA Alerts
FDA Approves Biosimilar for Various Inflammatory Diseases
08/31/2016
The FDA approved a biosimilar to treat RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
08/31/2016